title: Preparation and Evaluation of Chrysin Encapsulated in PLGA- PEG Nanoparticles in the T47-D Breast Cancer Cell Line.
abstract: BACKGROUND
  Polymeric nanoparticles are attractive materials that have been widely used in medicine for drug delivery, with therapeutic applications. In our study, polymeric nanoparticles and the anticancer drug, chrysin, were encapsulated into poly (D, L-lactic-co-glycolic acid) poly (ethylene glycol) (PLGA-PEG) nanoparticles for local treatment.
  
  
  METHODS
  PLGA: PEG triblock copolymers were synthesized by ring-opening polymerization of D, L-lactide and glycolide as an initiator. The bulk properties of these copolymers were characterized using 1H nuclear magnetic resonance spectroscopy and Fourier transform infrared spectroscopy. In addition, the resulting particles were characterized by scanning electron microscopy.
  
  
  RESULTS
  The chrysin encapsulation efficiency achieved for polymeric nanoparticles was 70% control of release kinetics. The cytotoxicity of different concentration of pure chrysin and chrysin loaded in PLGA-PEG (5-640μM) on T47-D breast cancer cell line was analyzed by MTT-assay.
  
  
  CONCLUSIONS
  There is potential for use of these nanoparticles for biomedical applications. Future work should include in vivo investigation of the targeting capability and effectiveness of these nanoparticles in the treatment of breast cancer.
authors.affiliation: Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran E-mail : Zarghami@tbzmed.ac.ir.
authors.forename: Sina
authors.initials: S
authors.lastname: Mohammadinejad
authors.forename: Abolfazl
authors.initials: A
authors.lastname: Akbarzadeh
authors.forename: Mohammad
authors.initials: M
authors.lastname: Rahmati-Yamchi
authors.forename: Saeid
authors.initials: S
authors.lastname: Hatam
authors.forename: Saeed
authors.initials: S
authors.lastname: Kachalaki
authors.forename: Sanaat
authors.initials: S
authors.lastname: Zohreh
authors.forename: Nosratollah
authors.initials: N
authors.lastname: Zarghami
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D019938:Cyclin D1 / Q000235:genetics; D004337:Drug Carriers / Q000008:administration & dosage* / Q000494:pharmacology; D016503:Drug Delivery Systems; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
chemical_list: C530104:CCND1 protein, human; D004337:Drug Carriers; D005419:Flavonoids; D012333:RNA, Messenger; D019938:Cyclin D1; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C043561:chrysin; D011092:Polyethylene Glycols